Market Share Liability and Enterprise Theory

When a person is harmed by a product but cannot pinpoint which specific manufacturer made the injurious item, traditional tort law leaves them without a remedy. This creates a profound injustice, allowing responsible parties to escape liability simply because their product is indistinguishable from others. Market share liability emerged as a revolutionary legal doctrine to solve this identification problem, particularly in mass-tort contexts like pharmaceuticals. This theory, along with the related enterprise theory, represents a fundamental shift in how courts balance the rights of injured plaintiffs against the principles of fair fault allocation among defendants.

The Problem of Unidentifiable Defendants and Alternative Causation

The foundational hurdle is the plaintiff's burden to prove that the defendant's specific conduct caused their injury. In a classic case like Summers v. Tice, where two hunters negligently shot in the plaintiff's direction but only one bullet hit him, the court shifted the burden of proof to the defendants. This "alternative liability" theory works when all possible wrongdoers are before the court. However, it collapses in mass-market scenarios involving a fungible product—like a generic drug or chemical—made by many manufacturers, where the plaintiff cannot possibly sue every single one and the specific injurious unit is lost or untraceable. Without a doctrinal innovation, manufacturers could act with impunity, knowing the structural impossibility of identification would shield them from liability.

The Sindell v. Abbott Laboratories Framework

The California Supreme Court's 1980 decision in Sindell is the cornerstone of market share liability. The case involved diethylstilbestrol (DES), a drug prescribed to prevent miscarriages that later caused cervical cancer in the daughters of the women who took it. Decades later, daughters could not identify which of hundreds of manufacturers produced the pills their mothers ingested. The court rejected traditional theories but crafted a new approach. It held that where a fungible product from multiple manufacturers causes injury, and all are negligent in failing to provide adequate warnings or in producing a defective product, the plaintiff may sue one or more manufacturers representing a "substantial share" of the market. Liability is then apportioned by market share, not by specific causation. If a defendant cannot prove its share, the court may assign liability based on its proportionate share of the plaintiff's damages relative to all defendants in the action. This theory is grounded in fairness and public policy: it ensures compensation for victims and places the loss on the industry that created the risk.

Key Requirements and Limitations of the Doctrine

Market share liability is not automatically applied; courts set specific gates to prevent overreach. First, the product must be truly fungible—functionally identical and interchangeable regardless of the manufacturer. DES met this standard; a pill from Company A was chemically identical to a pill from Company B. A car or a power tool likely would not, as designs and components vary. Second, plaintiffs must sue manufacturers representing a substantial share of the relevant market. This threshold ensures the theory is administratively feasible and that a meaningful portion of the industry is present to bear the loss. The definition of "substantial" and the geography of the relevant market (national, state, etc.) are often hotly contested issues. Third, all defendants must have been negligent or engaged in tortious conduct (e.g., producing a defectively designed product). The theory modifies proof of causation, not the underlying wrong. Finally, the plaintiff's inability to identify the precise manufacturer must not be due to their own lack of diligence.

Jurisdictional Variations and the "Enterprise Theory" Alternative

The adoption of Sindell is not uniform. Some states fully embrace it. Others reject it entirely, fearing it deviates too far from traditional causation. Many have created modified versions. New York, in Hymowitz v. Eli Lilly & Co., adopted a national market share approach, holding each liable defendant responsible for its share of the national DES market, irrespective of whether its product could have reached the specific plaintiff. This "collective liability" approach further eases the plaintiff's burden and simplifies litigation but increases the potential liability for manufacturers who did not actually distribute in the plaintiff's region. A distinct but related concept is the enterprise theory or industry-wide liability. Articulated in Hall v. E.I. Du Pont de Nemours & Co., this theory applies when an industry jointly controls the risks of its product through safety standards, industry-wide testing, or adherence to shared safety protocols. Here, the entire industry may be treated as a joint enterprise, and proof of membership in that cooperative venture can suffice to get to a jury on the issue of causation. While rarely applied, it represents a more radical collectivization of liability than market share, targeting the collaborative behavior of an industry.

Common Pitfalls

Misapplying Fungibility: A common error is assuming market share liability applies to any product from multiple manufacturers. The doctrine requires virtual identity. Attempting to apply it to non-fungible goods like machinery, where design differences matter, misunderstands its core rationale and will likely fail.

Confusing Market Share with Concerted Action: Students often conflate market share liability with traditional concerted action or conspiracy theories. Concerted action requires an explicit or tacit agreement to commit a tortious act. Market share liability requires no such agreement; it is a remedy of last resort for independently acting but similarly situated manufacturers of an identical, harmful product.

Overlooking Jurisdictional Doctrine: Assuming all states follow Sindell is a major pitfall. The theory remains a minority approach. Practitioners must meticulously research the law of the relevant jurisdiction to determine if market share, a variant of it, or a theory like alternative liability is even available.

Misunderstanding the Substantial Share Threshold: Plaintiffs may fail by not joining enough key players in the market. If the defendants before the court represent only a small fraction of the market, a court may dismiss the case for failing to meet the "substantial share" requirement, as the theory becomes unfair and statistically unworkable.

Summary

• Market share liability is an equitable doctrine that apportions liability among manufacturers of a fungible product based on their share of the market when the plaintiff cannot identify the specific source of injury, as established in Sindell v. Abbott Laboratories.
• Its application hinges on strict requirements: a functionally identical product, negligence by all defendants, the plaintiff's innocent inability to identify the source, and defendants representing a substantial share of the relevant market.
• Jurisdictions vary widely, with some adopting pure Sindell, others using a national market share model, many rejecting it, and a few employing the more radical enterprise theory for industries that jointly control risk.
• This area of law represents a persistent tension between the need to provide remedies for innocent victims and the foundational tort law principle that liability should be tied to proof of specific causation.